The Council for International Organizations of Medical Sciences Working Group XIV (CIOMS) has produced a draft report (the Draft Report) on the use of artificial intelligence (AI) in pharmacovigilance (PV). Torrey Cope, Anna Melin, and Andrew James provide insights on how life sciences companies can take steps to implement key concepts from the Draft Report.
Latest Post
More Posts
FDA Release of Complete Response Letters Raises Confidentiality, Disclosure Questions But Offers Insights for Development
Artificial Intelligence in Pharmacovigilance: Eight Action Items for Life Sciences Companies
Key Regulatory and Compliance Considerations for Early-Stage Life Sciences Companies and Their Investors
Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs
Digital Health and Artificial Intelligence: New Developments From President Biden’s Executive Order
Subscribe: Subscribe via RSS
Blogs
Firm/Org